The global portal hypertension management market is expected to reach a valuation of USD 3.05 billion in 2023, and is projected to exhibit a CAGR of 5% from 2023 to 2033. By the end of the aforementioned forecast period, the market for portal hypertension management is poised to reach USD 4.97 billion.
Generic drugs presently dominate the market, with the scope of diagnosis including vasopressin and its analogs, beta-blockers, and somatostatin and its analogs. This also shows promising prospects for treatment advancement and research. Moreover, As the most widely used imaging method for identifying portal hypertension, duplex Doppler ultrasonography has witnessed a substantial rise in demand. As a result, this attribute is also expected to spur market growth.
The most frequent cause of portal hypertension is cirrhosis. Cirrhosis is a liver condition that develops when scar tissue substitutes healthy liver cells. As a result, the number of individuals with this condition is expected to fuel market growth. Cirrhosis is more prevalent in men than in women, based on the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. As a result, the number of aged inhabitants is anticipated to contribute to a growing market.
Because of high technological advances in health care services and boosting prevalence and occurrence of beta-blocker demand, North America holds the largest market portion. Due to its rising elderly population and elevated prognosis rate, Asia-Pacific has the second-largest market revenue. As a result of consistent increases in the incidence and occurrence of rare diseases, as well as the enhancement of in-patient groups, North America is projected to account for the majority of the market in the years ahead.
The expansion of the liver transplantation segment can be credited to the global rise in demand for transplantable organs. Based on the USA Department of Health and Human Services, there were approximately 122,913 diagnoses in the United States hoping for organ transplants in 2019. As a result, sophisticated transplantation items for the intervention of organ damage are in great supply. As a result, the demand for the Liver Transplantation segment is growing. Also, Huge R&D investments, as well as the greater incidence and presence of cardiovascular problems, have expanded the market for beta blocker drugs, which is anticipated to propel this segment's growth during the forecast period. As a result, the Beta Blockers segment is expected to expand significantly.
Constructively approaching reimbursement can have a beneficial impact both during the late phases of the product's creation and long after the product has been launched. Organizations and academics are collaborating to identify obstacles and opportunities that may impact Portal Hypertension R&D. The therapies in development are centered on novel strategies to treat/improve disease symptoms. Companies involved are involved in the development of Portal Hypertension therapies. The introduction of new therapies will have a massive effect on the portal hypertension management market. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 3.05 Billion |
| Anticipated Forecast Value (2033) | USD 4.97 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The pandemic of COVID-19 has had a modest impact on medical systems and the industry. Furthermore, the disease outbreak was disrupting the healthcare supply chain, and several companies relocated to other geographic locations throughout that time to guarantee product availability and safeguard their supply chain. As a result, the market experienced a decline during the historical period.
However, now, that the industries are getting back to their normal functioning, the global demand for Portal Hypertension Management is projected to increase at a CAGR of 5% during the forecast period between 2023 and 2033, reaching a total of USD 4.97 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.
The increased incidence of portal hypertension in the elderly population is predicted to drive market expansion
Accordance to the American College of Cardiology, amidst getting the highest incidence of hypertension and the elevated risk of CV death and morbidity older adults are usually underdiagnosed for high blood pressure. Based on the National Health and Nutrition Examination Survey (NHANES), hypertension impacts 70% of people over the age of 65 in the United States.
This statistic will keep rising as the population ages. According to a Pew Research Center report, the older population in the United States will thrive to 81 million by 2050, up from 37 million in 2005. Besides this, significant R&D investments, in addition to the increasing proportion and occurrence of cardiovascular problems, have enhanced the demand for portal hypertension drugs.
The increasing incidences of liver cirrhosis propel portal hypertension management market
Based on the National Center for Biotechnology Information (NCBI), liver disease causes nearly 2 million deaths worldwide each year, with 1 million due to cirrhosis comorbidities and 1 million caused by viral hepatitis and hepatocellular carcinoma.
Cirrhosis is presently the 11th major cause of death, and liver cancer is the 16th major cause of death; together, these two diseases account for 3.5% of all global mortality. As a result, the rising prevalence of liver cirrhosis is expected to drive the portal hypertension management market.
Principal Consultant
Drugs side effects to Hinder Market Growth
Along with their necessary effects, the drugs may have some unintended consequences. Beta-blockers reduce heart rate. This can result in signs of low blood pressure.
Certain side effects of beta-blockers involve stomach aches, dizziness, diarrhea, or constipation, and also some people experience sexual dysfunction when obtaining them. These are a few of the considerations that the market is likely to face during the projected timeline.
Increased prevalence of cardiovascular diseases and liver cirrhosis drive regional market expansion
North America will have the greatest share of the revenue in 2023. The increased incidences of cardiovascular disorders, massive R&D capital, an aging population, well-established infrastructure, and rising demands for beta-blocker drugs are some of the aspects that the market is predicted to benefit from during the forecast timeframe.
Because of the rapid growth of beta blockers in North America, the region is predicted to have the largest market share during the projected period. Furthermore, the pervasiveness of cirrhosis in the United States was estimated to be 0.27% or 633,323 adults. Sixty-nine percent said they were oblivious they had liver disease. As a result, the prevalence of liver cirrhosis in the market is expected to drive market growth.
Because of the substantial population and expanding number of endoscopy disorder patients in Asia Pacific, the industry for portal hypertension management is anticipated to accelerate at the fastest rate over the projected period.
Furthermore, rising requirements for minimally invasive endoscopic processes and improved healthcare facilities are expected to accelerate the region's market growth. Furthermore, increased federal initiatives to modernize healthcare facilities and the continuous development of a start-up scenery are among the key factors publicizing the region's future growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospital Segment is Estimated to Hold the Largest Share
Based on end user, the global Portal Hypertension Management market is segmented into hospital, cardiac center, ambulatory center, and other.
The hospital segment held the largest share of the market in 2022. Moreover, the same segment is expected to register the highest CAGR from 2023 to 2033.
Liver Transplantation Segment is Estimated to Account for the Largest Share
The liver transplantation segment will experience extreme growth in the upcoming years as a consequence of the increasing prevalence of passive lifestyle choices, poor eating habits, alcoholism, and drug addiction, which are among the major aspects cruising the industry's expansion.
The aging population in addition to various charities for liver problems in the world's population, has created a market for liver transplants in different regions. These elements are predicted to propel the liver transplantation market.
Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some latest developments by manufacturers are below
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3.05 billion |
| Market Value in 2033 | USD 4.97 billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Ono Pharmaceutical Co., Ltd.; United Therapeutics Corporation; Chiasma Inc.; Genextra S.p.a.; Gilead Sciences Inc.; Debiovision, Inc.; Govind Ballabh Pant Hospital; Dr. Falk Pharma GmbH; Novartis AG; Sun Pharmaceuticals Industries Ltd. |
| Customization | Available Upon Request |
The projected CAGR of the portal hypertension management market by 2033 is 5%.
The projected market value by 2033 is USD 4.97 billion.
The market is estimated to secure a valuation of USD 3.05 billion in 2023.
The healthcare industry is the key consumer.
Gilead Sciences, Daiichi Sankyo, and Ono Pharmaceutical Co., Ltd. are the key players in the market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Liver Transplantation 5.2. Endoscopic Therapy 5.2.1. Banding 5.2.2. Balloon Tamponade 5.3. Shunting Procedures 5.3.1. Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt 5.3.2. Surgical Shunts 5.4. Drug Class 5.4.1. Octapeptides 5.4.2. Cofactors 5.4.3. PDE5 Inhibitors 5.4.4. Beta Blockers 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 6.1. Hospitals 6.2. Specialty Clinics 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Ono Pharmaceutical Co., Ltd. 15.2. United Therapeutics Corporation 15.3. Chiasma, Inc. 15.4. Genextra S.p.a. 15.5. Gilead Sciences, Inc. 15.6. Debiovision, Inc. 15.7. Govind Ballabh Pant Hospital 15.8. Dr. Falk Pharma GmbH 15.9. Novartis AG. 15.10. Sun Pharmaceuticals Industries Ltd. 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Portal Hypertension Management Market
